AtaGenix Laboratories
2025-05-30
Professional Protein Expression and Antibody Customization Services for Grass Carp C5a-CP Adjuvant Research
Grass carp C5a-CP shows exceptional potential as a vaccine adjuvant, enhancing IgM⁺ B cell phagocytic activity and vaccine efficacy. We provide professional protein expression and antibody customization services, including IgM-CH expression and purification and anti-C5aR polyclonal antibody production, supporting functional validation with high purity and specificity to advance fish vaccine adjuvant research.
2024-11-05
Stable Cell Lines
CHO stable cell lines were developed for recombinant antibody production, achieving over 3 g/L expression. Analyses of yield, stability, mycoplasma, purity, and affinity confirmed antibody quality. Additionally, a stable line for Varicella-Zoster Virus gE protein was validated, demonstrating biopharmaceutical versatility
2024-11-05
Bacillus subtilis
Two case studies highlight Bacillus subtilis as an efficient host for recombinant protein production. Protein A (20 mg/L, >90% purity) and Protein B (1 mg/L, >95% purity) demonstrate its scalability and reliability.
2024-11-05
Preparation of MHC-Peptide Complex Proteins
HLA-I protein and β2M were expressed and purified in E. coli, followed by refolding to form stable HLA/β2M/peptide complexes (pMHC). The addition of streptavidin (SA) enabled the formation of stable tetramers for downstream applications.
2024-11-05
E. coli Expression System
This study demonstrates the optimization of E. coli expression systems for recombinant protein and antibody fragment production. Strategies included host strain selection, periplasmic expression for proper folding, and refolding inclusion bodies into active soluble proteins. Results showcase high-quality protein expression and QC validation.
2024-11-04
Insect-Baculovirus Expression System Case Study
This case study demonstrates the use of the insect-baculovirus expression system for efficient production of recombinant proteins. The approach achieved high yields with proper folding and post-translational modifications, showcasing its reliability for complex protein expression.
2024-11-04
Mammalian HEK293 Expression
The results show that the SARS-CoV-2 S protein expressed in mammalian cells achieved high yields during purification, with clear target protein bands observed in elution fractions (E1-E8) and minimal impurities.
2024-10-21
XtenCHO™ High-Density Expression System
AtaGenix's XtenCHO™ high-density expression system demonstrates exceptional proliferation and yield advantages in therapeutic antibody production. Cells cultured in this system maintain high density and viability over 15 days, ensuring healthy growth. The system shows strong adaptability and production efficiency across various antibodies, providing robust support for efficient and stable therapeutic antibody manufacturing.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan